Clinical trials: Plasma Cell Tumor
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005641
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Colorectal Cancer, Hematologic Malignancy
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers.
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia
- Trial name
- NCT05400122
- Testing
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- David Wald
Multiple Myeloma
Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Multiple myeloma remains incurable disease in most patients . Cellular immunotherapy using dendritic cells is emerging as a useful immunotherapeutic modality to treat multiple myeloma.
- Trial name
- Vax-DC/MM (NCT02248402)
- Testing
- Vax-DC/MM
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Chonnam National University Hospital
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients
This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e.
- Conditions
- Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- NCT04688853
- Testing
- TEG002
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Gadeta B.V.
Multiple Myeloma, Hematologic Diseases
Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients
The purpose of this study is to compare clinical judgment and comprehensive geriatric assessment as screening tools for optimization of treatment for newly diagnosed elderly multiple myeloma patients.
- Trial name
- COMPASS (NCT02918695)
- Where
- 20 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Multiple Myeloma
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
The study consists of three parts: Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple…
- Trial name
- DynaMMic-1 (NCT05714839)
- Testing
- Belantamab, Belantamab mafodotin, Pomalidomide
- Where
- 44 sites in United States, Argentina and 11 more
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
RATIONALE: Biological therapies, such as a dendritic cell vaccine made with a patient's cancer cells, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00937183
- Testing
- autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine, autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine, autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine
- Where
- Poland
- Volunteers
- 12 people
- Sponsor
- Jan Walewski
Multiple Myeloma
Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy
Patients 60 to 70 years of age with newly diagnosed multiple myeloma were prospectively randomized between 4 cycles of anthracycline/dexamethasone-based induction chemotherapy (A1) or only 2 x 4 days of dexamethasone (A2).
- Trial name
- DSMM-II (NCT02288741)
- Testing
- Anthracycline/dexamethasone-based induction chemotherapy, Dexamethasone for control of symptoms, Tumor-reduction chemotherapy and stem cell mobilization
- Volunteers
- 549 people
- Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
Multiple Myeloma (MM)
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
The purpose of this project is to evaluate the impact of a 16-week lifestyle program that promotes changes in eating and exercise patterns.
- Trial name
- MFM (NCT07236502)
- Testing
- Immediate intervention, Waitlist
- Where
- 2 sites in United States
- Volunteers
- 184 people
- Sponsor
- Medical College of Wisconsin
Multiple Myeloma
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
This is a multi-centre Phase III randomized controlled study of patients with multiple myeloma (MM). Eligible patients who are not candidates for transplantation will be randomized to receive eight courses of…
- Trial name
- NCT00934154
- Testing
- Thalidomide, Melphalan+Prednisolone
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Cigdem Sahinbas YILMAZ
Relapsed/Refractory Multiple Myeloma
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM).
- Trial name
- NCT07760454
- Testing
- CT0596
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- UCARsgen Biotech Limited
Gastrointestinal Stromal Tumors
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Activating mutations of the kinases CKIT or PDGFRA can be detected in 90% of cases by DNA sequence analysis of a pathological specimen.
- Trial name
- NCT01462994
- Testing
- Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Technical University of Munich
Multiple Myeloma, Corneal Diseases
Corneal Findings in Patients Treated With Belantamab Mafodotin
In the upcoming years, more and more ophthalmologists will be confronted with patients receiving Belantamab mafodotin (Belamaf) treatment due to the promising effects on survival in multiple myeloma patients.
- Conditions
- Multiple Myeloma, Corneal Diseases, Corneal Cyst
- Trial name
- NCT05833737
- Testing
- Belantamab mafodotin
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Medical University of Vienna
Multiple Myeloma
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells.
- Trial name
- NCT04234022
- Testing
- Zn-DDC, Lanalidomide with Zn-DDC, Pomalidomide with Zn-DDC
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Myeloma Multiple
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma…
- Trial name
- NCT06245629
- Testing
- Bortezomib-bendamustine-melphalan
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Uppsala University
Multiple Myeloma
Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma
Compassionate use access to belantamab mafodotin (GSK2857916) (in combination with bortezomib/dexamethasone or pomalidomide/dexamethasone) for eligible participants with multiple myeloma previously treated with at least 1 prior…
- Trial name
- NCT03763370
- Testing
- Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd), Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
This protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus the association of…
- Trial name
- NCT03896737
- Testing
- Daratumumab plus Velcade Cyclophosphamide Dexamethasone, Velcade Thalidomide Dexamethasone
- Where
- 24 sites in Czechia, Greece and 1 more
- Volunteers
- 401 people
- Sponsor
- European Myeloma Network B.V.
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL)
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04488354
- Testing
- CLBR001 and SWI019
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Calibr, a division of Scripps Research
Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
The purpose of this study is to evaluate how tumors in patients with Waldenstrom's macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects (good and bad) it has on the cancer.
- Trial name
- NCT00142129
- Testing
- Bortezomib (Velcade)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01432353
- Testing
- DFRF4539A
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.